Longeveron (LGVN) Return on Capital Employed (2023 - 2026)
Longeveron (LGVN) recorded quarterly Return on Capital Employed of 200.88% in Q1 2026, up 23.9% quarter-over-quarter from 263.97% in Q4 2025, and down 11488.0% on a YoY basis from N/an in Q1 2025.
Longeveron (LGVN) Return on Capital Employed (2023 - 2026) Analysis & Trends
Longeveron's Return on Capital Employed history runs 4 years deep, the most recent figure standing at 200.88% for Q1 2026.
- In Q1 2026, Return on Capital Employed fell 11488.0% year-over-year to 200.88%; the TTM figure through Mar 2026 stood at 200.88% (down 11488.0% YoY), while the FY2025 annual figure was 168.47%, down 6671.0% from the prior year.
- Return on Capital Employed was 200.88% for Q1 2026 at Longeveron, up from 263.97% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 65.68% in Q4 2024 to a low of 364.83% in Q1 2024.
- Historically, Return on Capital Employed has averaged 171.48% across 4 years, with a median of 160.49% in 2024.
- The sharpest annual moves came in 2024 and 2025: Return on Capital Employed slumped 27268 bps in 2024, then jumped 27883 bps in 2025.
- A 4-year view of Return on Capital Employed shows it stood at 264.1% in 2023, then surged by 75 bps to 65.68% in 2024, then slumped by 302 bps to 263.97% in 2025, then advanced by 24 bps to 200.88% in 2026.
- The last three Return on Capital Employed figures came in at 200.88% (Q1 2026), 263.97% (Q4 2025), and 197.71% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 450.31% |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 51.73% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -107.40% |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -50.43% |
| 10 | Longeveron | 20.35 Bn | 20.33 Bn | 264,000.00 | -200.88% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -200.88% |
| Dec 31, 2025 | -263.97% |
| Sep 30, 2025 | -197.71% |
| Jun 30, 2025 | -125.74% |
| Mar 31, 2025 | -86.00% |
| Dec 31, 2024 | -65.68% |
| Sep 30, 2024 | -82.03% |
| Jun 30, 2024 | -160.49% |
| Mar 31, 2024 | -364.83% |
| Dec 31, 2023 | -264.10% |
| Sep 30, 2023 | -189.97% |
| Jun 30, 2023 | -135.71% |
| Mar 31, 2023 | -92.15% |